SAN FRANCISCO, Feb. 21, 2019 /PRNewswire-PRWeb/ -- Dosis, an AI-powered personalized dosing platform, and the developer of the Strategic Anemia Advisor (SAA) decision support tool, is now improving anemia management for chronic kidney disease patients and decreasing erythropoietin-stimulating agents (ESA) utilization at over 50 dialysis clinics nationwide. Seeking to drive a paradigm shift from the population-based dosing approaches that are the current standard of care, Dosis empowers healthcare providers to take a personalized approach to anemia management by determining a patient's unique response to ESA and recommending a dose to keep individual patients within their respective hemoglobin target ranges.
"Physicians recognize that exposure to high doses of ESA is associated with increased adverse cardiovascular events, so they try to use the minimum amount of ESA required to prevent transfusions," said Dr. George Aronoff, a former nephrology division chief at the University of Louisville and co-inventor of Strategic Anemia Advisor. "Dosis's Strategic Anemia Advisor is revolutionizing anemia management by offering physicians the tools to realize a 65% reduction in patient outlier hemoglobins and an increase in the percentage of patients within a hemoglobin target range, all while decreasing ESA exposure up to 50%."
More than 550,000 End-Stage Renal Disease (ESRD) patients in the U.S. are currently undergoing dialysis treatment, and the vast majority of those patients experience chronic anemia. ESRD costs Medicare $34B annually, which amounts to 7% of all Medicare expenditures, despite making up 1% of the Medicare patient population. This creates a need for innovative solutions that can improve the patient experience and clinical outcomes, while also addressing the high cost of care.
"The increased prevalence of lifestyle disorders like diabetes and hypertension in America has led to a major increase in the incidence chronic kidney disease, and for too long we've failed to bring innovative technology into renal care," said Shivrat Chhabra, CEO at Dosis. "At Dosis, we're addressing this problem head-on. Today, our company is providing more than 5,000 ESRD patients at dialysis centers across 10 states with a personalized dosing solution that allows patients' treatments to be optimized for their needs. Furthermore, we're enabling providers to enhance their existing anemia care program with a simple, cost-saving, and quickly implemented software-as-a-service solution."
Conventional population-based approaches require healthcare providers in dialysis clinics to spend around five minutes per patient to determine the next ESA dose. Dosis' personalized dosing platform provides a cloud-based reference tool, based on years of peer-reviewed research from the University of Louisville, that cuts the time spent on determining the new ESA dose to 30 to 45 seconds per patient. Moreover, this personalized approach allows clinics to reduce their ESA spend by up to $2,500 per patient per year.
Dosis' personalized dosing platform is scalable and shows promise for use with other drugs and on other conditions. However, the company plans to first bring additional precision dosing products to the renal care industry before exploring its use on conditions outside the renal space.
"The renal care industry is the ideal proving ground for innovations in personalized dosing and medicine," said Divya Chhabra, COO at Dosis. "Variables with adherence to medication often cause huge problems with the quality of data. That's not the case with dialysis patients, as you have a highly adherent patient population that goes to the clinic three times per week to be treated."
Dialysis clinics and centers interested in Dosis can sign up for a demo here.
About Dosis
Dosis, an AI-powered personalized dosing platform, is the developer of the Strategic Anemia Advisor (SAA) clinical decision support tool. SAA is currently revolutionizing anemia management for more than 5,000 dialysis patients at over 50 dialysis clinics across the country by supporting healthcare providers with determining a patient's unique response to erythropoietin-stimulating agents (ESA) and recommending personalized dosages that keep individual patients within their hemoglobin target ranges. Dosis is headquartered in San Francisco. For more information, visit dosisinc.com.
SOURCE Dosis
Share this article